Detection of Mutations in Selected Proto-Oncogenes of Canine Lymphoma

Bona, G; Šiviková, Katarı́na

doi:10.1515/fv-2017-0036

Cited by 2 publications

(1 citation statement)

References 13 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As c-Kit mutations are mainly reported in canine mast-cell tumors, few studies have investigated its mutation in canine leukemia and lymphoma. A nonsense mutation at codon 425 of exon 8 (rs22299980 A > G, Thr425 =) was observed in 73% (30/41) of dogs with acute myeloid leukemia 35 , and a similar polymorphism of c-Kit T425 = was described in mixed-breed dogs with lymphoma 36 . Although the c-Kit mutation was rarely reported in canine nodal lymphomas, we decided to choose the SNP location of the c-Kit gene and investigate in canine DLBCL with an increased sample size.…”

Section: Discussionmentioning

confidence: 86%

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Sirivisoot

Kasantikul

Techangamsuwan

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in dogs with a multicentric form. This study aimed to assemble 41 variants of the previously reported genes and to investigate these variants in canine DLBCL using the Agena MassARRAY platform. These variants were chosen based on the high prevalence observed in canine B- and T-cell lymphomas, their significance for target therapy, and compatibility for multiplex PCR amplification. Lymph node biopsy was performed from 60 dogs with B-cell lymphoma comprising 47 purebred and 13 crossbred dogs. All dogs presented single nucleotide polymorphisms (SNPs) at HYAL4 and SATB1 genes. The lesser mutual SNPs were observed at SEL1L, excluding a cocker spaniel, and c-Kit, with the exception of a pug and a French bulldog. Even though no statistical association was noted between each SNP and dog breed, purebreds were 3.88 times more likely to have a SNP at FLT3 rs852342480 (95%CI 0.50–45.03, p = 0.26), 3.64 times at TRAF3 F306X (95%CI 0.58–42.50, p = 0.43) and 2.66 times at TRAF3 E303EX (95%CI 0.56–13.12, p = 0.31). Also, DLBCL dogs (CHOP-based treatment) with c-Kit T425= had a poorer prognosis with shorter median overall survival times (OST) than dogs with the wild type. Dogs treated with COP chemotherapy and contained 3–5 variants at SEL1L were associated with decreased median OST. Therefore, this SNP’s lymphoma panel provides valuable information that we can use to outline a prognosis and develop a treatment plan for the targeted therapy of each dog.

show abstract

Section: Discussionmentioning

confidence: 86%

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Sirivisoot

Kasantikul

Techangamsuwan

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

Single nucleotide polymorphism profiles of canine T-cell and null-cell lymphomas

Sirivisoot,

Kasantikul,

Techangamsuwan

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

BackgroundThe histopathological classification of T-cell lymphoma (TCL) in humans has distinctive mutational genotyping that suggests different lymphomagenesis. A similar concept is assumed to be observed in dogs with different TCL phenotypes.ObjectiveThis study aimed to identify the previously reported single-nucleotide polymorphisms (SNPs) in both human beings and dogs in canine TCLs and null-cell lymphomas (NCLs) and to design compatible oligonucleotides from each variant based on the multiplex polymerase chain reaction.MethodsGenomic DNA was extracted from 68 tumor specimens (62 TCLs and 6 NCLs) and 5 buffy coat samples from dogs with TCL. Four TCL subtypes and NCL were analyzed in 44 SNPs from 21 genes using the MassARRAY.ResultsThe greatest incidences of SNPs observed in all TCL subtypes and NCL ware SATB1 c.1259A > C, KIT c.1275A > G, SEL1L c.2040 + 200C > G, and TP53 c.1024C > T, respectively. Some SNP locations were statistically significant associated with NCL, including MYC p.S75F (p = 0.0003), TP53 p.I149N (p = 0.030), PDCD1 p.F37LX (p = 0.012), and POT1 p.R583* (p = 0.012).ConclusionEach TCL histological subtype and NCL are likely to contain distinctive mutational genetic profiles, which might play a role in lymphoma gene-risk factors and might be useful for selecting therapeutic target drugs for each canine patient.

show abstract

Detection of Mutations in Selected Proto-Oncogenes of Canine Lymphoma

Abstract: ABSTRACT

Cited by 2 publications

References 13 publications

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY

Single nucleotide polymorphism profiles of canine T-cell and null-cell lymphomas

Contact Info

Product

Resources

About